0001628280-26-032290
SEC filingQ1 delivered strong revenue acceleration and margin expansion, reflecting operational leverage from integrated portfolio post-merger, with robust cash generation supporting strategic flexibility amid ongoing integration.
Revenue increased 27.0% year-over-year to $759.9 million in Q1 FY2026 from $598.1 million, propelled by the integration of enabling technologies with the core musculoskeletal solutions portfolio. This acceleration underscores the synergies from recent strategic combinations, enabling broader adoption as management anticipates continued rise in utilization across surgical applications.
Gross profit advanced 30.6% to $525.8 million, lifting the gross margin to 69.2% from the prior-year level. The expansion reflects operational leverage at scale, favorable product mix shifts toward higher-margin offerings, and efficiencies in cost of sales—including shipping and handling classified per company policy. These dynamics demonstrate the resilience of the integrated platform amid post-merger normalization.
Operating income surged 55.0% to $150.4 million, representing 19.8% of revenue, as profitability gains outpaced topline growth. This improvement highlights disciplined expense management and the benefits of portfolio optimization, even as the business navigates integration-related adjustments like stock-based compensation under ASC Topic 420 where applicable.